Expanded Access: Past, Present and Future Improvements
Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning
Expanded access is a program that provides patients with investigational medicinal products (IMP) for treatment purposes. These patients are often excluded from clinical trials but could still benefit from access to the drugs, biologics or medical devices being tested. While, in concept, expanded access represents a way to help more patients receive new and developing treatments, in reality, the process is complex and often misunderstood.
Related Education Resources.
All ResourcesGDPR Considerations for DtP Supply Chains
Topics: Regulatory, Supply Chain
Guidance Document
Free
FDA Policy for REMS Reqmts during COVID-19
Topics: Health Care, Pharma Industry, Strategic Planning
Guidance Document
Free
Countdown to Brexit: Can your clinical supply chain pass the Brexit pressure test
Topics: Pharma Industry, Politics
White Paper
Members